Be the Match Donor Drive
December 3, 2013
7 a.m.-5 p.m.
The James Lobby and 322 James
Qualifying donors of ages 18-44 may register
Exclusions for participation include:
- Diagnosed with HIV (Aids)
- Severe medical arthritic conditions
- Asthma requiring regular/daily use of oral (pill) steroids
- Breathing problems such as emphysema, sleep apnea or cystic fibrosis
- Certain autoimmune diseases such as; Rheumatoid arthritis, lupus, fibromyalgia, MS, Psoriasis, Chron’s disease, Ulcerative colitis
- Chronic Back pain requiring ongoing medical treatment
- Herniated disc
- Back surgery in the past 2 years
- History of spine fracture
- History of hip or pelvic fracture or repair
- Serious bleeding problems such as; hemophilia, Factor V Leiden, ever had a clot, require anticoagulants, and aplastic anemia
- Brain surgery or injury or multiple concussions
- Cancer that was not “in situ” (diagnosed at a very early stage (0)
- Any chemical dependency
- Mental health conditions such as schizophrenia disorder or delusional
- Diabetes requiring insulin or any injectable medications to treat diabetes
- Heart disease
- History of stroke or transient ischemic attack
- Diagnosed with hepatitis B or C
- Positive confirmatory test for hepatitis B or C
- Carrier for hepatitis B or C
- Serious or chronic kidney problems
- Serious liver disease
- Men who have had sex with other men within the past 5 years
- Received transplant of human organs, marrow, or live tissue from animals
- Active Tuberculosis
- Maximum body weight of associated with a body mass index (BMI) of 40
Every four minutes, one person is diagnosed with a blood cancer. Every 10 minutes, someone dies from a blood cancer. Seventy percent of all patients who need a transplant don’t have a matched donor in their family. Be The Match Registry is operated by the National Marrow Donor Program (NMDP), a nonprofit organization that’s dedicated to creating an opportunity for all patients to receive the marrow or umbilical cord blood transplant they need. A patient’s likelihood of finding a matching donor on the Be The Match Registry is estimated to range from 66-93% depending on race and ethnicity.
For questions, please contact Gail Risley at 614-293-3154, or call The James Line at 614-293-5066.
Leukemia is a cancer that begins in blood-forming tissues of the body, such as bone marrow. Although people often think of leukemia as a childhood disease – primarily because it accounts for 30 percent of childhood cancer cases and is the chief cause of death by disease in children ages 1 to 14 – it actually is diagnosed 10 times more often in adults.
At The James, we have experts in this highly specialized field who have dedicated their lives to supporting and caring for leukemia patients and their families. Our team approach provides the best research and treatment, putting our physicians and researchers on the leading edge of advances in detecting and treating leukemia. Our leukemia program differs from others in that our inpatient care unit is dedicated solely to patients with this diagnosis, with both physicians and nurses who are specialized in the management and complications of this disease. Leukemia management is a very specialized field that has changed dramatically over the past several years, emphasizing the importance of a physician/healthcare professional team focused on treatment of this disease.
Physicians and researchers at Ohio State's Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute are continually seeking new answers to questions about leukemia. Recent research advancements include:
- Received a five-year, $6.25 million grant from the Leukemia & Lymphoma Society to develop new therapies and improve current therapies for chronic lymphocytic leukemia (CLL), one of the most common forms of adult leukemia.
- Received a five-year, $11.8 million grant from the National Cancer Institute to study biological mechanisms of chronic lymphocytic leukemia and translate basic research findings into clinical trials for patients with this disease.
- Receipt of multiple NCI grants to develop novel targeted therapies for acute myeloid leukemia, acute lymphoblastic lymphoma, and chronic lymphocytic leukemia. This represents the signature statement of this program, to develop novel, non-toxic therapies for leukemia.
- Conducted a study showing that a new strain of transgenetic mouse offers the first animal model for chronic lymphocytic leukemia and should aid in the development of drugs for this disease.
- Participation on an international team of researchers led by Clara D. Bloomfield, MD, OSU cancer scholar and senior adviser, and OSUCCC Director Michael A. Caligiuri, MD, that has discovered multiple genetic markers that identify patients with acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) who do not respond as effectively to standard treatment without these markers.
- A $6.2 million grant from the National Cancer Institute to continue assessing molecular markers in leukemia and how they may be linked to treatment and survival. Michael Caligiuri, MD, will lead several investigators working in six study areas involving approximately 500 leukemia patients.
- Received a $100,000 grant from The V Foundation for Cancer Research for a two-year study of a transgenic mouse model that may help clarify the role of a specific gene in disrupting normal biological processes and triggering leukemia and lympoma.
- Discovery of hairy cell leukemia by Bertha A. Bouroncle, MD.
- Development of pentostatin to treat hairy cell leukemia, other types of leukemia and graft-versus-host disease. This project was led by Eric Kraut, MD, and Michael Grever, MD.
- Development of fludarabine for treatment of chronic lymphocytic leukemia (CLL) and lymphoma. Research by Michael Grever, MD.
- Development of two monoclonal antibodies (rituximab and alemtuzumab) for the treatment of CLL.
- Original organizing members of an NCI-sponsored national consortium related to CLL. John Byrd, MD, and Michael Grever, MD, are focused on pharmacology of new therapies for the treatment of CLL.
This section of the Web site will give you access to:
If you have questions about leukemia, please call The James Line – a free cancer information resource and physician referral service – at 614-293-5066 or 1-800-293-5066 (outside Franklin County) or e-mail now. The James Line oncology nurses can
be reached Monday-Friday 8:00 a.m.-5:00 p.m. (except weekends and